Chair: Rafael Rosell Under the Auspices of: Registrations: www.doctaforum.com/gecp
Thursday, 21 st of November 2013 08:00-10:00 CLINICAL SESSION Isabel lbover Fundación Hospital Son Llàtzer, Palma de Mallorca Mª Dolores Isla Hospital Clínico Univ. Lozano Blesa, Zaragoza 08:00-08:15 New developments in SCLC Edurne Arriola Hospital del Mar, Barcelona 08:15-08:30 Imaging techniques for assessing systemic therapies Juan Arenas 08:30-08:45 New combinations and concurrent CT/RT in Locally Advanced NSCLC Natividad Martínez Hospital General Universitario, Elche (Alicante) 08:45-09:00 Comprehensive strategies in the treatment of metastatic NSCLC Luis Paz-Ares Hospital Universitario Virgen del Rocío, Sevilla 09:00-09:15 Anti-angiogenesis in NSCLC achievements and new deals (ANGIOMET Trial) Delvys Rodríguez Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria 09:15-09:30 Special populations in NSCLC: elderly, PS2 María Jové ICO, Hospital de Bellvitge, L Hospitalet de Llobregat (Barcelona) 09:30-09:45 Immunotherapy in NSCLC: anti-pd1 and anti-pdl1 Santiago Ponce Hospital Universitario 12 de Octubre, Madrid 09:45-10:00 Conclusions 10:30 WELCOME Rafael Rosell 10:40-11:30 SESSION 1: UPDATES ON CLINICAL TRIALS Rosario García Campelo Complejo Hospitalario Universitario, A Coruña Jürgen Wolf Center for Integrated Oncology, Cologne (Germany) 10:40-10:50 BELIEF Enric Carcereny
10:50-11:00 GOAL Rosario García Campelo Complejo Hospitalario Universitario, A Coruña 11:00-11:10 EUCROSS Jürgen Wolf Center for Integrated Oncology, Cologne (Germany) 11:10-11:20 NVALT trial in second line squamous cell carcinoma with FGFR1 amplification Harry J. M. Groen University Medical Center Groningen, Groningen (The Netherlands) 11:20 11:30 Foretinib/erlotinib in EGFR WT NSCLC, second line resistant EGFR mutated patients and ROS1 positive, crizotinib resistant patients Niki Karachaliou 11:30-12:40 SESSION 2: CLINICAL IMPLICATIONS OF RESEARCH IN PATHOLOGY AND LUNG CANCER BIOLOGY Egbert F. Smit VU University Medical Center, Amsterdam (The Netherlands) José L. Ramírez 11:30-11:40 Multi-assay genotyping of druggable driver mutations Katharina König Uniklinik Köln, Cologne (Germany) 11:40-11:50 Relevance of FISH for ALK, ROS1 and RET translocations Hans-Ulrich Schildhaus University Hospital Göttingen, Göttingen (Germany) 11:50-12:00 Concordance of FISH and PCR for EML4-ALK Cristina Teixidó Pangaea Biotech, Barcelona 12:00-12:10 EML4-ALK and other mutations in blood platelets Thomas Würdinger VU University Medical Center, Amsterdam (The Netherlands) 12:10-12:20 MLPA assay for multiplexing mutations, copy numbers and fusion transcripts José L. Ramírez ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona) 12:20-12:40 Questions and answers. Conclusions Egbert F. Smit VU University Medical Center, Amsterdam (The Netherlands) KEYNOTE LECTURE 12:40-13:10 Using tumor growth rates to differentiate cancer therapies Antonio Tito Fojo National Cancer Institute, Center for Cancer Research,Bethesda (Maryland, USA) 13:10-14:10 Lunch
Thursday, 21 st of November 2013 14:10-14:40 SESSION 3: BREAKTHROUGHS IN SCLC AND MESOTHELIOMA Rolf A. Stahel University Hospital Zurich, Zurich (Switzerland) Felipe Cardenal ICO, Hospital Duran i Reynals, L Hospitalet de Llobregat (Barcelona) 14:10-14:20 HIPPO/YAP pathway for targeted therapy Emanuela Felley-Bosco University Hospital Zurich, Zurich (Switzerland) 14:20-14:30 State of the art in mesothelioma management Rolf A. Stahel University Hospital Zurich, Zurich (Switzerland) 14:30-14:40 Improving curability in SCLC: A feasible objective? Pilar Lianes Hospital de Mataró, Mataró (Barcelona) 14:40-15:40 SESSION 4: TARGETED THERAPIES AND NOVEL AGENTS IN STAGE IV NSCLC Manuel Dómine Fundación Jiménez Díaz, Madrid Enriqueta Felip Hospital General Vall d Hebron, Barcelona 14:40-14:50 Whole genome sequencing for precise targeted therapy Trever G. Bivona University of California, San Francisco (California, USA) 14:50-15:00 Understanding resistance to EGFR TKIs in EGFR mutant NSCLC through a serial rebiopsy program Margarita Majem Hospital de la Santa Creu i Sant Pau, Barcelona 15:00-15:10 c-met mab development in lung cancer Volker Wacheck Lilly (Austria) 15:10-15:20 Targeted therapy in NSCLC driven by HER2 insertions Solange Peters Lausanne Cancer Center, Centre Hospitalier Universitaire Vaudois Lausanne (Switzerland) 15:20-15:40 Questions and answers. Conclusions Enriqueta Felip Hospital General Vall d Hebron, Barcelona 15:40-16:20 SESSION 5: LOCALLY ADVANCED NSCLC Wilfried Eberhardt West German Cancer Center. University of Essen Medical School, Essen (Germany) Pilar Garrido Hospital Universitario Ramón y Cajal, Madrid
15:40-15:50 Chemoradiotherapy: Déjà vu or a new reality? Wilfried Eberhardt West German Cancer Center. University of Essen Medical School Essen (Germany) 15:50-16:00 State of the art in treatment Pilar Garrido Hospital Universitario Ramón y Cajal, Madrid 16:00-16:10 Integration of novel targeted therapies into radiotherapy for lung cancer Mariano Provencio Hospital Universitario Puerta de Hierro, Majadahonda (Madrid) 16:10-16:20 Questions and answers. Conclusions Arturo Navarro ICO, Hospital Duran i Reynals, L Hospitalet de Llobregat (Barcelona) 16:20-16:40 Coffee break 16:40-18:00 SESSION 6: ADVANCES IN EARLY STAGE NSCLC Florentino Hernando Trancho Hospital Clínico Universitario San Carlos, Madrid 16:40-16:50 Management of stage I NSCLC patients Enriqueta Felip Hospital General Vall d Hebron, Barcelona 16:50-17:00 Adjuvant chemotherapy in stage I high risk patients José Ramón Jarabo Hospital Clínico Universitario San Carlos, Madrid 17:00-17:10 Customized adjuvant chemotherapy in stage II and III - the SCAT experience 17:10-17:20 State of the art of adjuvant chemotherapy in Stage II and III NSCLC patients Ángel Artal Hospital Universitario Miguel Servet, Zaragoza 17:20-17:30 State of the art in surgery for early NSCLC. Does the number of resected lymph nodes matter? Laura Romero Hospital General Vall d Hebron, Barcelona 17:30-17:40 CTCs in monitoring resected NSCLC Andreas-Claudius Hoffmann West German Cancer Center. Uniklinikum Essen, Essen (Germany) 17:40-18:00 Questions and answers. Conclusions Javier de Castro Hospital Universitario La Paz, Madrid
Friday, 22 nd of November 2013 08:00-08:30 SLCG PLENARY SESSION 08:30-08:45 PLENARY LECTURE 08:30-08:45 Moving forward to synthetic lethal approaches for improving survival in NSCLC Rafael Rosell 08:45-09:55 SESSION 7: MOLECULAR SCREENING FOR SYNTHETIC LETHALITY APPROACHES Niki Karachaliou Trever G. Bivona University of California, San Francisco (California, USA) 08:45-08:55 KRAS mutations Rolf A. Stahel University Hospital Zurich, Zurich (Switzerland) 08:55-09:05 BRAF mutations José M. Sánchez Hospital Universitario de La Princesa, Madrid 09:05-09:15 Predicting resistance by selection of signaling pathways Niki Karachaliou 09:15-09:25 Combination targeted therapy in EGFR mutant patients Trever G. Bivona University of California, San Francisco (California, USA) 09:25-09:35 Combination targeted therapy in EML4-ALK translocated patients Santiago Viteri 09:35-09:55 Questions & answers. Conclusions Santiago Ponce Hospital Universitario 12 de Octubre, Madrid 09:55-10:15 Coffee break KEYNOTE LECTURE 10:15-10:45 Improving the activity of epigenetic therapies Susan E. Bates National Cancer Institute, Center for Cancer Research, Bethesda (Maryland, USA) 10:45-10:55 SESSION 8: STATE OF THE ART IN TRANSLATIONAL RESEARCH Miguel A. Molina Mariano Provencio Hospital Universitario Puerta de Hierro, Majadahonda (Madrid)
10:45-10:55 p53 mutational analysis for clinical applications Miguel A. Molina 10:55-11:05 Transcriptional regulators for refinement of lung cancer subtypes Cristina Teixidó Pangaea Biotech, Barcelona 11:05-11:15 From the bench to the bed: the unmet need for progress Egbert F. Smit VU University Medical Center, Amsterdam (The Netherlands) 11:15-11:25 Lessons from the BREC study: opportunities remain for customizing chemotherapy Manuel Cobo Hospital Universitario Carlos Haya, Málaga 11:25 11:35 Elderly patients: how old is too old for translational research? 70, 90? Alain Vergnenègre Cluzeau University Hospital, Limoges (France) 11:35-11:55 Questions and answers. Conclusions Noemí Reguart Hospital Clínic Universitari, Barcelona 11:55 12:25 SESSION 9: CRUCIAL ROLE OF THE THORACIC SURGEON Laureano Molins Hospital Clínic, Barcelona Nicolás Moreno Hospital Universitario Virgen del Rocío, Sevilla 11:55-12:05 Surgical implications of the new pathological classification of adenocarcinoma Íñigo Royo Hospital Universitario Miguel Servet, Zaragoza 12:05-12:15 VATS resections in NSCLC: Oncological Results Pedro López de Castro Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona) 12:30-12:25 Surgical management of metachronic and synchronic second primary lung tumors Íker López Sanz Hospital General Vall d Hebrón, Barcelona 12:25-12:40 PLENARY LECTURE 12:25-12:40 DNA stability and cisplatin resistance in NSCLC Ken O Byrne Queensland University of Technology, Brisbane (Queensland, Australia) 12:40-12:50 Closing remarks Rafael Rosell Hospital General Universitario de Alicante, Alicante
VENUE Auditori AXA Avda. Diagonal, 547 08029 Barcelona (Spain) LANGUAGE Lectures will be delivered in English or Spanish. CREDITS Accredited by the European Society for Medical Oncology Educational Committee Working Group for its medical oncology certification approval program with 10 ESMO-MORA category 1 points. ORGANIZING & SCIENTIFIC COMMITTEE Carlos Camps, Hospital General Universitario, Valencia Enric Carcereny, Felipe Cardenal, ICO, Hospital Duran i Reynals, L Hospitalet de Llobregat (Barcelona) Javier de Castro, Hospital Universitario La Paz, Madrid Manuel Cobo, Hospital Universitario Carlos Haya, Málaga Manuel Dómine, Fundación Jiménez Díaz, Madrid Rosario García Campelo, Complejo Hospitalario Universitario, A Coruña Florentino Hernando-Trancho, Hospital Clínico Universitario San Carlos, Madrid Dolores Isla, Hospital Clínico Universitario Lozano Blesa, Zaragoza Eloísa Jantús, Hospital General Universitario, Valencia Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona, Teresa Morán, Mariano Provencio, Hospital Universitario Puerta de Hierro, Majadahonda (Madrid) Noemí Reguart, Hospital Clínic Universitari, Barcelona Rafael Rosell, José Javier Sánchez, Universidad Autónoma de Madrid José Miguel Sánchez, Hospital Universitario de la Princesa, Madrid Miquel Taron, Pangaea Biotech, Barcelona MAJOR SPONSORS OTHER SPONSORS CONFERENCE SECRETARIAT Monasterios de Suso y Yuso 34, 4-14-2 28049 Madrid Tel.: +34 91 372 02 03 - Email: gecp2013@doctaforum.com www.doctaforum.com/gecp